Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07558785

Telemedicine Self-examination of Speech and Memory for Rapid Detection of Cognitive Impairments Using Machine Learning Methods

Early cognitive disorders diagnosis is becoming increasingly important due to population aging. The most common causes include Alzheimer's disease and frontotemporal dementia. These diseases are also manifested by changes in speech. NLP allows us to identify and classify these changes. The project aims to develop a web application for self-assessment and automated detection of cognitive disorders from speech. The application will have a form of a dialogue system using machine learning methods. The novelty of this approach is the possibility of an efficient self-assessment of a wide spectrum of the Czech population from their homes and an automated evaluation of test results. Early detection can be followed by a more detailed diagnosis and adequate treatment.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Mild Cognitive Impairment (MCI) Alzheimer Disease Alzheimer Disease (AD) Brain Diseases Central Nervous System Diseases Cognition Disorders Cognitive Dysfunction Dementia Frontotemporal Degeneration (FTD) Mental Disorders Mild Cognitive Impairment (MCI) Amnestic Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Tauopathies

Age range

40 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Západočeská univerzita v Plzni / Fakulta aplikovaných věd, Pilsen, Czechia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

for the group of healthy participants:

  • age over 45 years
  • Czech as the native language
  • must meet the criteria in a questionnaire with questions focused on a history of brain injury or psychiatric history or medication use
  • must achieve normal scores on questionnaires assessing mood

Inclusion criteria

for the group of patients:

  • be diagnosed with mild neurocognitive impairment (MCI) or neurocognitive disorder (dementia) according to the international DSM-5 criteria

Treatment and study plan

The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)

Diagnostic Test

A brief individually administered battery to measure cognitive decline or improvement across five domains in ages 12 to 89 years 11 months.

the Mississippi Aphasia Screening Test

Diagnostic Test

he Mississippi Aphasia Screening Test (MAST) was developed as a brief, repeatable screening measure for individuals with severely impaired communication/language skills.

Amnesia Light and Brief Assessment (ALBA)

Diagnostic Test

Very brief test used to measure deficits of more cognitive functions (short-term, episodic, semantic amnesia, sensory and motor aphasia, apraxia, psychomotor speed).

The Picture naming and immediate recall test (PICNIR)

Diagnostic Test

Very brief test used to measure deficits of more cognitive functions (short-term, episodic, semantic amnesia, sensory and motor aphasia, apraxia, psychomotor speed).

Geriatric Depression Scale (GDS-15)

Diagnostic Test

The Geriatric Depression Scale (GDS-15), used to screen for depression in adults aged 55 and older, consists of 15 items that assess mental health based on feelings over the past week.

The Beck Anxiety Inventory (BAI)

Diagnostic Test

A formative assessment and rating scale of anxiety.

Digitial Diagnostics of Dementia (DDD)

Diagnostic Test

Our experimental screening battery developed for this study.

Primary outcomes

  1. The difference in results between groups of patients with cognitive impairment and healthy individuals in individual parts of our experimental neuropsychological battery Diagnostic Test: Digitial Diagnostics of Dementia (DDD)

    Time frame: Through study completion, an average of 2 years

  2. Correlation of the results of our experimental battery (DDD) with RBANS

    Time frame: Through study completion, an average of 2 years

  3. Correlation of the results of our experimental battery (DDD) with MAST

    Time frame: Through study completion, an average of 2 years

  4. Correlation of the results of our experimental battery (DDD) with ALBA

    Time frame: Through study completion, an average of 2 years

  5. Correlation of the results of our experimental battery (DDD) with POBAV

    Time frame: Through study completion, an average of 2 years

Sponsors and collaborators

Lead sponsor

Faculty Hospital Kralovske Vinohrady

Other Gov

Registry information

Important dates

Study start
2023
Primary completion
2025
Study completion
2026
First posted
Apr 30, 2026
Registry last updated
Apr 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.